news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

reprinted from: general comprehensive of the central commission for discipline inspection: younger than the blue

there has been a lot of news about general motors group’s pharmaceutical companies recently.

on september 11, the central commission for discipline inspection published an article titled "three-court trial: corruption or illegal operation of similar business", reporting on the case of yang jie, former chairman of china pharmaceutical shanghai general runda co., ltd. on july 12, 2024, yang jie was convicted of illegal operation of similar business and sentenced to three years in prison, suspended for four years, and fined 1 million yuan.

on september 12, "integrity universal" released an announcement that zhuang awei, former assistant to the general manager of hubei universal pharmaceutical co., ltd., was subject to disciplinary review and supervisory investigation. this is the second time that the former general manager and financial director of general pharmaceuticals have been investigated, and the former assistant general manager has also been investigated.

yang jie, sentenced to three years in prison and fined 1 million yuan

yang jie has served as deputy general manager of hainan general sanyo pharmaceutical co., ltd., a subsidiary of china pharmaceutical and healthcare industry co., ltd., deputy general manager of the pharmaceutical industry division of china pharmaceutical and healthcare industry co., ltd., director of the business coordination office, general manager of the pharmaceutical commercial division, and chairman of shanghai general runda medical technology co., ltd., a subsidiary of china pharmaceutical and healthcare industry co., ltd.

the case was filed for review and investigation in 2022

on july 25, 2022, the qinhuai district supervisory committee of nanjing city opened an investigation into yang jie's suspected serious violations of duty, and took detention measures against yang jie on august 8.

on august 15, 2022, the discipline inspection commission of china pharmaceutical and healthcare industry co., ltd. filed a case against yang jie. on october 18 of the same year, it was decided to extend yang jie's detention for three months, and on december 23 of the same year, yang jie's detention measures were lifted.

on march 31, 2023, the qinhuai district supervision committee transferred the case of yang jie suspected of illegally operating similar businesses to the qinhuai district people's procuratorate for review and prosecution.

on april 3, 2023, the party committee of china pharmaceutical healthcare industry co., ltd. expelled yang jie from the party and removed him from public office.

on december 14, 2023, the qinhuai district people's procuratorate filed a public prosecution with the qinhuai district people's court on the charge that yang jie was suspected of illegally operating similar businesses.

on july 12, 2024, the qinhuai district people's court sentenced yang jie to three years in prison, suspended for four years, and fined him rmb 1 million for the crime of illegally operating a similar business. the judgment has now come into effect.

resisting organizational review and violating political discipline

from november 2021 to february 2022, the discipline inspection commission of china pharmaceutical health industry co., ltd. conducted an initial investigation into clues related to yang jie's problems, and went to sanyo pharmaceutical to retrieve business transaction information between a medical device company and sanyo pharmaceutical, as well as information on yang jie's appointment and removal. after yang jie found out, he repeatedly asked his former subordinate fang about the work trends and content of the discipline inspection commission staff.

afterwards, yang jie took the initiative to contact the relevant leaders of the discipline inspection commission of china pharmaceutical and healthcare industry co., ltd. and explained the abnormal payment transactions between a medical device company and sanyo pharmaceutical co., ltd.account transfer behavior, to the organizationproviding false information,he interfered with the organization's review activities by concealing the fact that he had set up a medical device company and distributed a capsule produced and sold by sanyo pharmaceutical company.

he established a company with others and took advantage of his position to make a profit of more than 8 million yuan.

violation of integrity discipline. in june 2003, yang jie, his wife liu, and his boss xia jointly invested in a medical device company with a registered capital of rmb 500,000 (the same currency below). yang jie and his wife liu each held 40% of the shares, and xia held 20% of the shares. the company was engaged in the purchase and sale of drugs and medical devices.

in july 2010, the company increased its capital to 24.5 million yuan, with yang jie holding 80% of the shares. in may 2021, yang jie transferred all the shares to his son yang.the company was still in operation at the time of the incident.

the crime of illegally operating the same type of business. from july 2007 to july 2022, while serving as deputy general manager of sanyo pharmaceutical and deputy general manager of the pharmaceutical industry division of china pharmaceutical and healthcare industry co., ltd., yang jie took advantage of his position to add his company to the list of pharmaceutical agents, responsible for the jiangsu region, and sold a capsule produced and sold by sanyo pharmaceutical through a medical device company with xia moumou (sanyo pharmaceutical can sell a capsule directly or through other agents after producing it); he obtained illegal profits of more than 8 million yuan.

yang jie used his position to allow a medical device company to occupy sanyo pharmaceutical's sales market in jiangsu province for a long time, which endangered the management and market order of sanyo pharmaceutical, was socially harmful, and the amount of illegal profits he obtained was extremely huge, which constituted the crime of illegally operating a similar business according to the law.

sentenced to three years in prison

in this case, yang jie's behavior damaged the management order and market order of state-owned enterprises, but he returned all the illegal gains of more than 8 million yuan, truthfully confessed all the criminal facts after being arrested, and had a good attitude of remorse. yang jie has been dismissed from public office and objectively has no risk of reoffending. after investigation and evaluation by relevant departments, the sentence of probation will not cause major adverse effects on the community where he lives. he has signed the "confession and acceptance of punishment" before the court. taking into account yang jie's criminal circumstances, remorseful behavior and other circumstances, the application of probation to him can better reflect the principle of proportionality between crime, responsibility and punishment.

in the end, the court ruled that yang jie was guilty of illegally operating a similar business and sentenced him to three years in prison, suspended for four years, and fined him 1 million yuan. the decision has now come into effect.

general pharmaceuticals, former assistant to general manager investigated

on april 16, hubei general pharmaceutical co., ltd. general manager wang jian and financial director dai xuhui were investigated on suspicion of serious violations of law.

on september 12, "integrity general" issued an announcement: zhuang awei, former assistant to the general manager of hubei general pharmaceutical co., ltd., was subject to disciplinary review and supervisory investigation.

this is the second time that the former general manager and financial director of general pharmaceuticals have been investigated, and the former assistant general manager has also been investigated.

according to the discipline inspection and supervision group of general technology group and the discipline inspection and supervision commission of yichang city, hubei province, zhuang awei, former assistant to the general manager of hubei general pharmaceutical co., ltd., is suspected of serious violations of discipline and laws, and is currently undergoing disciplinary review and supervision investigation by the discipline inspection and supervision group of general technology group and the supervision commission of yichang city, hubei province.

general pharmaceuticals group's anti-corruption campaign has resulted in multiple investigations

on august 26, lianjie general announced that zhang jie (a third-level executive in the group), senior director of key accounts in the medical resources management department of general global medical group co., ltd. of general technology group, is suspected of serious violations of law and is currently under supervision and investigation by the discipline inspection and supervision group of general technology group and the supervisory committee of shiyan city, hubei province.

since the beginning of this year, yang leijun, project manager of global medical business department 3, and zhang jie, senior director of key accounts of the medical resources management department, have been investigated for suspected serious violations of law.

since 2023, many people in the group's pharmaceutical companies have been investigated, including dong quanlei, general manager of business department 1 of general global medical group co., ltd., former assistant general manager liu yihong, wang jian, general manager of hubei general pharmaceutical co., ltd. under china pharmaceutical health industry co., ltd., financial director dai xuhui, lu wenxue, project manager of business department 1 of general global medical group co., ltd. of general technology group, project manager yao ruiqing, former project manager wang lizhu, and yang leijun, project manager of business department 3 of general global medical group co., ltd. under general technology group.